Katsutoshi Shoda1,2, Daisuke Ichikawa3, Yuji Fujita1,2, Kiyoshi Masuda2, Hidekazu Hiramoto1, Junichi Hamada1,2, Tomohiro Arita1, Hirotaka Konishi1, Shuhei Komatsu1, Atsushi Shiozaki1, Naoki Kakihara4, Kazuma Okamoto1, Hiroki Taniguchi4, Issei Imoto5, Eigo Otsuji1. 1. Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. 2. Department of Human Genetics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. 3. Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. ichikawa@koto.kpu-m.ac.jp. 4. Department of Surgery, Kyoto Second Red Cross Hospital, 355-5 Haruobi-cho, Kamigyo-ku, Kyoto, 602-8026, Japan. 5. Department of Human Genetics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. issehgen@tokushima-u.ac.jp.
Abstract
BACKGROUND: We previously demonstrated the potential of circulating tumor DNA (ctDNA) for the amplification of detecting HER2 in patients with gastric cancer (GC). In the present study, we focused on the clinical courses of patients who developed recurrence with GC, and investigated the potential clinical utility of the ddPCR-based HER2 copy number (CN) as a marker for the temporal and/or spatial heterogeneities of GC during treatment progress. METHOD: We enrolled 30 healthy volunteers and 60 patients with GC who underwent surgery, including 17 patients who developed recurrence. Using ribonuclease P RNA component H1 (RPPH1) as a reference gene, plasma HER2 to RPPH1 ratios (the HER2 ratio) were determined using ddPCR. RESULTS: The preoperative plasma HER2 ratio correlated with the tumor HER2 status (p < 0.001), and sensitivity and specificity were 0.733 and 0.933, respectively. Analyses of plasma samples during the postoperative follow-up periods revealed that high plasma HER2 ratios were detected at the time of recurrence in 7 of 13 cases, which were diagnosed as being HER2 negative at the time of surgery. These results were supported by continuously increasing HER2 ratios thereafter with the progression of recurrent cancer. CONCLUSION: The plasma HER2 ratio determined by ddPCR is a repeatable and noninvasive approach for real-time evaluations of the HER2 status to monitor the effects of treatments for patients with HER2-positive GC and enable treatment options for patients with HER2-negative GC but positive conversion of the HER2 status after recurrence.
BACKGROUND: We previously demonstrated the potential of circulating tumor DNA (ctDNA) for the amplification of detecting HER2 in patients with gastric cancer (GC). In the present study, we focused on the clinical courses of patients who developed recurrence with GC, and investigated the potential clinical utility of the ddPCR-based HER2 copy number (CN) as a marker for the temporal and/or spatial heterogeneities of GC during treatment progress. METHOD: We enrolled 30 healthy volunteers and 60 patients with GC who underwent surgery, including 17 patients who developed recurrence. Using ribonuclease P RNA component H1 (RPPH1) as a reference gene, plasma HER2 to RPPH1 ratios (the HER2 ratio) were determined using ddPCR. RESULTS: The preoperative plasma HER2 ratio correlated with the tumorHER2 status (p < 0.001), and sensitivity and specificity were 0.733 and 0.933, respectively. Analyses of plasma samples during the postoperative follow-up periods revealed that high plasma HER2 ratios were detected at the time of recurrence in 7 of 13 cases, which were diagnosed as being HER2 negative at the time of surgery. These results were supported by continuously increasing HER2 ratios thereafter with the progression of recurrent cancer. CONCLUSION: The plasma HER2 ratio determined by ddPCR is a repeatable and noninvasive approach for real-time evaluations of the HER2 status to monitor the effects of treatments for patients with HER2-positive GC and enable treatment options for patients with HER2-negative GC but positive conversion of the HER2 status after recurrence.
Authors: Fiona M F Lun; Rossa W K Chiu; Kun Sun; Tak Y Leung; Peiyong Jiang; K C Allen Chan; Hao Sun; Y M Dennis Lo Journal: Clin Chem Date: 2013-07-15 Impact factor: 8.327
Authors: Benjamin J Hindson; Kevin D Ness; Donald A Masquelier; Phillip Belgrader; Nicholas J Heredia; Anthony J Makarewicz; Isaac J Bright; Michael Y Lucero; Amy L Hiddessen; Tina C Legler; Tyler K Kitano; Michael R Hodel; Jonathan F Petersen; Paul W Wyatt; Erin R Steenblock; Pallavi H Shah; Luc J Bousse; Camille B Troup; Jeffrey C Mellen; Dean K Wittmann; Nicholas G Erndt; Thomas H Cauley; Ryan T Koehler; Austin P So; Simant Dube; Klint A Rose; Luz Montesclaros; Shenglong Wang; David P Stumbo; Shawn P Hodges; Steven Romine; Fred P Milanovich; Helen E White; John F Regan; George A Karlin-Neumann; Christopher M Hindson; Serge Saxonov; Bill W Colston Journal: Anal Chem Date: 2011-10-28 Impact factor: 6.986
Authors: Alexandra S Whale; Jim F Huggett; Simon Cowen; Valerie Speirs; Jacqui Shaw; Stephen Ellison; Carole A Foy; Daniel J Scott Journal: Nucleic Acids Res Date: 2012-02-28 Impact factor: 16.971
Authors: H Kinugasa; K Nouso; T Tanaka; K Miyahara; Y Morimoto; C Dohi; T Matsubara; H Okada; K Yamamoto Journal: Br J Cancer Date: 2015-04-21 Impact factor: 7.640
Authors: Elisa Danese; Anna Maria Minicozzi; Marco Benati; Martina Montagnana; Elisa Paviati; Gian Luca Salvagno; Gabriel Lima-Oliveira; Milena Gusella; Felice Pasini; Giuseppe Lippi; Gian Cesare Guidi Journal: PLoS One Date: 2015-05-06 Impact factor: 3.240
Authors: Jian Yuan Goh; Min Feng; Wenyu Wang; Gokce Oguz; Siti Maryam J M Yatim; Puay Leng Lee; Yi Bao; Tse Hui Lim; Panpan Wang; Wai Leong Tam; Annette R Kodahl; Maria B Lyng; Suman Sarma; Selena Y Lin; Alexander Lezhava; Yoon Sim Yap; Alvin S T Lim; Dave S B Hoon; Henrik J Ditzel; Soo Chin Lee; Ern Yu Tan; Qiang Yu Journal: Nat Med Date: 2017-09-25 Impact factor: 53.440
Authors: Yoshiaki Shoji; Satoru Furuhashi; Daniel F Kelly; Anton J Bilchik; Dave S B Hoon; Matias A Bustos Journal: Clin Exp Metastasis Date: 2021-05-05 Impact factor: 5.150